Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 11/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18133916 | 0.92 | KRAS (0.49) | KRASCRBN | |
| SCHEMBL31658110 | 0.90 | TLR9 (0.38) | KRAS | |
| SCHEMBL18128518 | 0.90 | TLR9 (0.38) | KRAS | |
| SCHEMBL18133917 | 0.88 | SLC29A1 (0.36) | KRASNAMPTALDH1A1 | |
| SCHEMBL19681378 | 0.82 | KRAS (0.47) | KRASCRBNP2RY12 | |
| SCHEMBL18128713 | 0.76 | KRAS (0.54) | KRASALDH1A1 | |
| SCHEMBL21370924 | 0.76 | KRAS (0.60) | KRAS | |
| SCHEMBL16637205 | 0.75 | ABL1 (0.39) | KRAS | |
| SCHEMBL18128469 | 0.75 | KRAS (0.70) | KRAS | |
| SCHEMBL16637053 | 0.73 | KRAS (0.35) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-09-19 | — | — | US | disclosed |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3280708-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Araxes Pharma LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2016164675-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885F10 1270/4885NAMPT 3415/4885 |
| US-10246424-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | KRAS 1/4885F10 1270/4885NAMPT 3415/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KRAS 1/4885F10 1270/4885NAMPT 3415/4885 |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | KRAS 1/4885F10 1270/4885NAMPT 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.